iSAM Funds (UK)’s Protagonist Therapeutics PTGX Stock Holding History

iSAM Funds (UK)’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-3,118	Closed	-$207K	–	628
2025 Q3	$207K	Buy	+3,118	New	+$177K	0.04%	409

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

iSAM Funds (UK)'s PTGX Position: Q4 2025 in Review

iSAM Funds (UK) sold out of Protagonist Therapeutics (PTGX) in Q4 2025, closing a stake of 3,118 shares — an estimated $207K sold.

iSAM Funds (UK) first reported a position in PTGX in Q3 2025 and held it in 1 quarter. The position peaked at $207K in Q3 2025. 316 funds tracked by Wall St. Rank hold PTGX as of Q4 2025.

iSAM Funds (UK) reported no remaining Protagonist Therapeutics position as of Q4 2025 after selling out during the quarter.
iSAM Funds (UK) sold 3,118 Protagonist Therapeutics shares in Q4 2025, an estimated $207K.
iSAM Funds (UK) first reported a position in Protagonist Therapeutics in Q3 2025 and held it in 1 quarter.
iSAM Funds (UK)'s Protagonist Therapeutics position peaked at $207K in Q3 2025.
316 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2025.

Based on iSAM Funds (UK)'s 13F filing for Q4 2025, filed 17 Feb 2026.